<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308853</url>
  </required_header>
  <id_info>
    <org_study_id>31GB0607</org_study_id>
    <nct_id>NCT01308853</nct_id>
  </id_info>
  <brief_title>Macrolane for Enhancement of the Shape and Fullness of the Female Breast</brief_title>
  <official_title>An Open, Multi-center Study Evaluating Treatment Procedure, Efficacy and Safety of Macrolane VRF30 for Enhancement of the Shape and Fullness of the Female Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates treatment procedure, efficacy and safety of Macrolane for female breast
      enhancement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the injection technique and treatment outcome by stepwise inclusion and
      treatment of Macrolane for female breast enhancement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Breasts With Successful Placement of the Implant Posterior to the Mammary Gland at 6 Weeks After Treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>Inclusion was made in steps in group of 4 subjects. The subjects were followed-up with MRI 1-5 days after the injection to document correct injection technique. Before the next group were treated, the Expert Group evaluated the 6-week follow-up results of the previous group. The injection procedure was, if necessary, changed in accordance with specifically pre-defined parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Breasts With Improvement as Assessed by the Investigator</measure>
    <time_frame>6 weeks</time_frame>
    <description>Esthetic improvement was evaluated using the Global Esthetic Improvement Scale (GEIS).
The scale has five grades ranging from worse to very much improved. Subjects defined as &quot;at least improved&quot; are assessed as improved, much improved or very much improved.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Breast Enhancement</condition>
  <arm_group>
    <arm_group_label>Macrolane</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Macrolane</intervention_name>
    <description>Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.</description>
    <arm_group_label>Macrolane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female between 25 and 50 years of age with small breasts seeking enhancement of the
             shape and fullness of the breast

        Exclusion Criteria:

          -  Unreasonable expectations

          -  Any medical condition that may interfere with the treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Heden, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademikliniken, Stockholm, Sweden</affiliation>
  </overall_official>
  <results_reference>
    <citation>Hed√©n P, Olenius M, Tengvar M. Macrolane for breast enhancement: 12-month follow-up. Plast Reconstr Surg. 2011 Feb;127(2):850-60. doi: 10.1097/PRS.0b013e318200ae57.</citation>
    <PMID>20966812</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 22, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <results_first_submitted>November 13, 2018</results_first_submitted>
  <results_first_submitted_qc>June 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Macrolane</title>
          <description>Open label
Device: Macrolane. Treatment: Initial injection (including touch-up) of a maximum of 120 ml/breast.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insertion of permanent implants</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Macrolane</title>
          <description>Open label
Device: Macrolane. Treatment: Initial injection (including touch-up) of a maximum of 120 ml/breast.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Breasts With Successful Placement of the Implant Posterior to the Mammary Gland at 6 Weeks After Treatment</title>
        <description>Inclusion was made in steps in group of 4 subjects. The subjects were followed-up with MRI 1-5 days after the injection to document correct injection technique. Before the next group were treated, the Expert Group evaluated the 6-week follow-up results of the previous group. The injection procedure was, if necessary, changed in accordance with specifically pre-defined parameters.</description>
        <time_frame>6 weeks</time_frame>
        <population>All included participants (Intention To Treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Macrolane</title>
            <description>Open label
Device: Macrolane. Treatment: Initial injection (including touch-up) of a maximum of 120 ml/breast.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Breasts With Successful Placement of the Implant Posterior to the Mammary Gland at 6 Weeks After Treatment</title>
          <description>Inclusion was made in steps in group of 4 subjects. The subjects were followed-up with MRI 1-5 days after the injection to document correct injection technique. Before the next group were treated, the Expert Group evaluated the 6-week follow-up results of the previous group. The injection procedure was, if necessary, changed in accordance with specifically pre-defined parameters.</description>
          <population>All included participants (Intention To Treat)</population>
          <units>Breasts</units>
          <param>Number</param>
          <units_analyzed>Breasts</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Breasts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Breasts With Improvement as Assessed by the Investigator</title>
        <description>Esthetic improvement was evaluated using the Global Esthetic Improvement Scale (GEIS).
The scale has five grades ranging from worse to very much improved. Subjects defined as &quot;at least improved&quot; are assessed as improved, much improved or very much improved.</description>
        <time_frame>6 weeks</time_frame>
        <population>Intention to treat. Data from 1 participant not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Macrolane</title>
            <description>Open label
Device: Macrolane. Treatment: Initial injection (including touch-up) of a maximum of 120 ml/breast.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Breasts With Improvement as Assessed by the Investigator</title>
          <description>Esthetic improvement was evaluated using the Global Esthetic Improvement Scale (GEIS).
The scale has five grades ranging from worse to very much improved. Subjects defined as &quot;at least improved&quot; are assessed as improved, much improved or very much improved.</description>
          <population>Intention to treat. Data from 1 participant not available.</population>
          <units>percentage of breasts</units>
          <param>Number</param>
          <units_analyzed>breasts</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>breasts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day 0 up until 24 months after injection</time_frame>
      <desc>Systematic assessments:
Subject diary for collection of expected adverse events. Collection of related and unrelated adverse events at each clinical visit following injection when subjects were asked &quot;Since your last clinical visit have you had any health problems?&quot; Mammography performed. Breast examinations Laboratory assessments</desc>
      <group_list>
        <group group_id="E1">
          <title>Macrolane</title>
          <description>Open label
Device: Macrolane. Treatment: Initial injection (including touch-up) of a maximum of 120 ml/breast.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Capsular contracture associated with breast implant</sub_title>
                <counts group_id="E1" events="22" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Implant site nodule</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Breast discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Individual publications shall not be made prior to the first, multi-center publication of the results of the multicenter study. The Investigator shall have the right to publish the results of his work. Any publication or presentation by Institution and/or Principal Investigator shall be submitted to Q Med for review and comment no less than 60 days before submission to allow Q Med to determine whether any patentable invention or Confidential Information would be disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Per Hed√©n</name_or_title>
      <organization>Akademikliniken, Stockholm, Sweden</organization>
      <phone>+46 8 614 54 00</phone>
      <email>per.heden@ak.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

